Nanogen, Pathway Diagnostics Sign License Agreement

Nanogen and Pathway Diagnostics announced that they have entered into a nonexclusive, worldwide license agreement under which Nanogen will develop diagnostic products that detect genetic variations associated with responses to antidepressant and antipsychotic therapeutics. The companies have begun work on developing a molecular diagnostic product that could be used to select the most appropriate drug and dosage for patients treated for psychiatric diseases. Specific financial terms of the agreement were not disclosed.

mysan.de (http://www.mysan.de/article61298.html)